WraSer announced it has received approval from the Food and Drug Administration (FDA) for Trezix (acetaminophen, caffeine, dihydrocodeine bitartrate) Capsules for the management of moderate to moderately severe pain.
Trezix is a Schedule III controlled substance that combines acetaminophen 320.5mg, caffeine 30mg, and dihydrocodeine bitartrate 16mg. Acetaminophen is a non-opiate, non-salicylate analgesic and antipyretic. Caffeine, a CNS and cardiovascular stimulant, acts as an analgesic adjuvant. Dihydrocodeine bitartrate is a semi-synthetic narcotic analgesic that exerts its effects on the CNS and smooth muscle organs.
Trezix will be available as 320.5mg/30mg/16mg capsules in 100-count bottles. It is expected to launch latest December 15, 2014 and is also available under the Company’s mail-prescription program called SAVER EXPRESS.
For more information call (601) 605-0664 or visit TrezixRx.com.